Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms

Graefes Arch Clin Exp Ophthalmol. 2020 Apr;258(4):735-741. doi: 10.1007/s00417-020-04608-9. Epub 2020 Jan 21.

Abstract

Purpose: We evaluated changes in the numbers of microaneurysms (MAs) on fluorescein angiography (FA) and indocyanine green angiography (IA) in eyes with diabetic macular edema (DME) following intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents.

Methods: Twenty-one eyes of 16 patients with DME were included in this retrospective study. All patients received an initial loading dose of three monthly injections of anti-VEGF agents; thereafter, they received a pro re nata regimen for at least 12 months of follow-up. FA and IA images were obtained before and at 6 months after the initial injection.

Results: The median numbers of MAs significantly decreased from six (interquartile range [IQR] 3-7) MAs in early-phase FA, three (IQR 3-5) leaky MAs in late-phase FA, and two (IQR 1-4) MAs in late-phase IA at baseline to two (IQR 1-3) MAs in early-phase FA, one (IQR 0-2) leaky MA in late-phase FA, and one (IQR 0-2) MA in late-phase IA at 6 months (P < 0.0001 for all). Only the median numbers of MAs in late-phase IA at baseline and at 6 months were significantly higher in the recurrent DME group (13 eyes) than in the non-recurrent DME group (five eyes) (three [IQR 2-4] vs one [IQR 1-2], one [IQR 0.5-2] vs zero [P = 0.0185 and P = 0.009]).

Conclusion: Intravitreal injection of anti-VEGF agents reduced the numbers of MAs in patients with DME. The numbers of MAs detected by late-phase IA might be useful predictors of DME recurrence.

Keywords: Anti-vascular endothelial growth factor therapy; Diabetic macular edema; Diabetic retinopathy; Fluorescein angiography; Indocyanine green angiography; Microaneurysm.

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / administration & dosage
  • Coloring Agents / pharmacology
  • Diabetic Retinopathy / complications*
  • Diabetic Retinopathy / diagnosis
  • Diabetic Retinopathy / drug therapy
  • Female
  • Fluorescein Angiography / methods*
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Indocyanine Green / pharmacology*
  • Intravitreal Injections
  • Macula Lutea / diagnostic imaging*
  • Macular Edema / complications
  • Macular Edema / diagnosis*
  • Macular Edema / drug therapy
  • Male
  • Microaneurysm / diagnosis*
  • Microaneurysm / drug therapy
  • Microaneurysm / etiology
  • Middle Aged
  • Prospective Studies
  • Ranibizumab / administration & dosage*
  • Tomography, Optical Coherence / methods
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity

Substances

  • Angiogenesis Inhibitors
  • Coloring Agents
  • Vascular Endothelial Growth Factor A
  • Indocyanine Green
  • Ranibizumab